doi: 10.1161/CIRCULATIONAHA.106.634709
(Circulation. 2006;114:912-920.)
© 2006 American Heart Association, Inc.
Hypertension |
Short-Term Administration of a Cell-Permeable Caveolin-1 Peptide Prevents the Development of Monocrotaline-Induced Pulmonary Hypertension and Right Ventricular Hypertrophy
From the Departments of Cancer Biology and Biochemistry & Molecular Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pa (J.-F.J., I.M., M.P.L.); Department of Medicine, Montreal Heart Institute, Montreal, Quebec, Canada (J.D.); and Departments of Pathology and Medicine, Albert Einstein College of Medicine, Bronx, NY (H.B.T.).
Correspondence to Michael P. Lisanti MD, PhD, Thomas Jefferson University, 233 S 10th St, Bluemle Bldg, Room 933B, Philadelphia, PA 19107. E-mail Michael.Lisanti{at}jefferson.edu
Received April 18, 2006; revision received June 29, 2006; accepted July 7, 2006.
Background— Caveolins (Cavs), the principal structural proteins of caveolar microdomains, have been implicated in the development of pulmonary hypertension (PH). Mice with homozygous deletion of the Cav-1 gene develop PH and right ventricular hypertrophy (RVH). Reductions in pulmonary Cav-1 expression have been shown in several animal models of PH and in patients with severe PH. Whether in vivo modulation of Cav-1 expression could affect the development of PH and RVH remains unknown. Therefore, we investigated the effect of in vivo administration of a Cav-1 mimetic peptide on the development of monocrotaline (MCT)-induced PH.
Methods and Results— Thirty minutes after injection of saline or 60 mg/kg MCT, rats were assigned to receive a daily injection of saline, a peptide corresponding to the homeodomain of the Drosophila transcription factor antennapedia (AP; 2.5 mg · kg–1 · d–1), or a peptide consisting of the Cav-1–scaffolding domain coupled to AP (AP-Cav; 2.5 mg · kg–1 · d–1) for 2 weeks. MCT and MCT+AP rats developed PH with respective right ventricular systolic pressures of 40.2±1.5 and 39.6±1.5 mm Hg. Administration of AP-Cav to MCT rats significantly reduced the right ventricular systolic pressure to 30.1±1.3 mm Hg. MCT and MCT+AP rats also developed pulmonary artery medial hypertrophy and RVH, which was normalized by administration of AP-Cav. Mechanistically, the development of PH was associated with reduced expression of pulmonary Cav-1 and Cav-2, hyperactivation of the STAT3 signaling cascade, and upregulation of cyclin D1 and D3 protein levels, all of which were prevented by administration of AP-Cav.
Conclusions— Short-term administration of a Cav-based cell-permeable peptide to MCT rats prevents the development of pulmonary artery medial hypertrophy, PH, and RVH.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  S. Gur, P. J. Kadowitz, S. Thammasitboon, J. A. Lasky, and W. J. G. Hellstrom Characterization of Erectile Function in Monocrotaline-Treated Pulmonary Hypertensive Rats J Androl, September 1, 2009; 30(5): 495 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu, R. H. Henning, M. Sandovici, J. J. van der Want, W. H. van Gilst, and H. Buikema Enhanced myogenic constriction of mesenteric artery in heart failure relates to decreased smooth muscle cell caveolae numbers and altered AT1- and epidermal growth factor-receptor function Eur J Heart Fail, March 1, 2009; 11(3): 246 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Huang, P. M. Kaminski, J. G. Edwards, A. Yeh, M. S. Wolin, W. H. Frishman, M. H. Gewitz, and R. Mathew Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1250 - L1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Maniatis, V. Shinin, D. E. Schraufnagel, S. Okada, S. M. Vogel, A. B. Malik, and R. D. Minshall Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1-/- mice Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L865 - L873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mukhopadhyay, M. Shah, F. Xu, K. Patel, R. M. Tuder, and P. B. Sehgal Cytoplasmic provenance of STAT3 and PY-STAT3 in the endolysosomal compartments in pulmonary arterial endothelial and smooth muscle cells: implications in pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L449 - L468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Patel, S. Zhang, F. Murray, R. Y. S. Suda, B. P. Head, U. Yokoyama, J. S. Swaney, I. R. Niesman, R. T. Schermuly, S. S. Pullamsetti, et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension FASEB J, September 1, 2007; 21(11): 2970 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Sehgal and S. Mukhopadhyay Dysfunctional Intracellular Trafficking in the Pathobiology of Pulmonary Arterial Hypertension Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 31 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Sehgal and S. Mukhopadhyay Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs? Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H77 - H85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, and M. Shah Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1526 - L1542. [Abstract] [Full Text] [PDF]
|
|